Market Cap 504.05M
Revenue (ttm) 44.55M
Net Income (ttm) -83.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -188.06%
Debt to Equity Ratio -0.82
Volume 919,100
Avg Vol 3,679,526
Day's Range N/A - N/A
Shares Out 122.05M
Stochastic %K 68%
Beta 1.54
Analysts Strong Sell
Price Target $8.89

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 941 1900
Address:
30 Technology Drive, Warren, United States
Noahman
Noahman Apr. 4 at 1:56 PM
$AQST does anyone remember after resubmission of neffy it took fda to aprove the indication? I was thinking it was approved 2 months prior to pdufa date. Just curious 🤔
1 · Reply
UnderLion16
UnderLion16 Apr. 3 at 12:19 PM
$AQST https://www.linkedin.com/posts/underlion16_clear-path-forward-share-7445807113504702466-Sa74?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo
0 · Reply
kibli
kibli Apr. 3 at 4:17 AM
$AQST As of April 2026, FDA Commissioner Dr. Marty Makary is prioritizing the, rising epidemic of food allergies by focusing on evidence-based policy, particularly the early introduction of allergens to induce immunity. He has criticized past dietary guidelines for contributing to a "man-made" peanut allergy epidemic by advising against early allergen exposure. “We made a terrible, tragic mistake as a medical profession giving parents the wrong recommendation to avoid peanut and other allergens until a child turns three years of age, ignoring a basic principle in immunology known as oral tolerance, whereby the body’s developing immune system benefits from exposures to allergens as early as five, six, seven, months of age,” he said. “And we now know from good research published by some of the experts here that that helps significantly reduce peanut allergies and other food allergies later in life.” https://www.megynkelly.com/2026/02/26/fda-convenes-panel-to-address-surge-in-food-allergies/#:~:text=“We%20made%20a%20terrible%2C%20tragic,your%20baby%2C”%20he%20suggested.
0 · Reply
kibli
kibli Apr. 3 at 4:12 AM
$AQST The FDA is continuing its quest to speed up drug approvals and make more drugs available over the counter (OTC), FDA Commissioner Marty Makary, MD, MPH, said Wednesday. https://www.medpagetoday.com/publichealthpolicy/fdageneral/120604
1 · Reply
LDstocks2023
LDstocks2023 Apr. 2 at 8:19 PM
$AQST thing fuckin sucks
0 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 6:50 PM
🐉 $AQST CALL — DragonAlgo® Signal Contract: AQST CALL Expiry: 2026-05-15 | Strike: $2.00 | Type: CALL Option Plan (premium): Entry: $2.12 Stop: $1.53 TP1: $2.76 TP2: $3.61 TP3: $5.10 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Golfnstock
Golfnstock Apr. 2 at 4:37 PM
$AQST so Eli Lilly’s weight lose drug was just approved and I had to chuckle at one of the comments listed “The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times. The agency said it reviewed the company's application in 50 days.” Let’s hope this bodes well for our resubmission
1 · Reply
BigGainTom
BigGainTom Apr. 2 at 3:25 PM
$AQST nice rally
1 · Reply
richb477
richb477 Apr. 2 at 3:42 AM
$AQST Needed in every licker room j
0 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 1:15 AM
🐉 $AQST CALL — DragonAlgo® Signal Contract: AQST CALL Expiry: 2026-05-15 | Strike: $2.00 | Type: CALL Option Plan (premium): Entry: $2.15 Stop: $1.55 TP1: $2.79 TP2: $3.65 TP3: $5.16 🔗 https://dragonalgo.com
0 · Reply
Latest News on AQST
Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation

Mar 13, 2026, 5:38 AM EDT - 22 days ago

Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation


Aquestive Therapeutics: Looking For The PDUFA Run-Up

Jan 9, 2026, 4:21 AM EST - 3 months ago

Aquestive Therapeutics: Looking For The PDUFA Run-Up


Aquestive Therapeutics: A Measured Bet

Oct 12, 2025, 2:57 AM EDT - 6 months ago

Aquestive Therapeutics: A Measured Bet


Noahman
Noahman Apr. 4 at 1:56 PM
$AQST does anyone remember after resubmission of neffy it took fda to aprove the indication? I was thinking it was approved 2 months prior to pdufa date. Just curious 🤔
1 · Reply
UnderLion16
UnderLion16 Apr. 3 at 12:19 PM
$AQST https://www.linkedin.com/posts/underlion16_clear-path-forward-share-7445807113504702466-Sa74?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo
0 · Reply
kibli
kibli Apr. 3 at 4:17 AM
$AQST As of April 2026, FDA Commissioner Dr. Marty Makary is prioritizing the, rising epidemic of food allergies by focusing on evidence-based policy, particularly the early introduction of allergens to induce immunity. He has criticized past dietary guidelines for contributing to a "man-made" peanut allergy epidemic by advising against early allergen exposure. “We made a terrible, tragic mistake as a medical profession giving parents the wrong recommendation to avoid peanut and other allergens until a child turns three years of age, ignoring a basic principle in immunology known as oral tolerance, whereby the body’s developing immune system benefits from exposures to allergens as early as five, six, seven, months of age,” he said. “And we now know from good research published by some of the experts here that that helps significantly reduce peanut allergies and other food allergies later in life.” https://www.megynkelly.com/2026/02/26/fda-convenes-panel-to-address-surge-in-food-allergies/#:~:text=“We%20made%20a%20terrible%2C%20tragic,your%20baby%2C”%20he%20suggested.
0 · Reply
kibli
kibli Apr. 3 at 4:12 AM
$AQST The FDA is continuing its quest to speed up drug approvals and make more drugs available over the counter (OTC), FDA Commissioner Marty Makary, MD, MPH, said Wednesday. https://www.medpagetoday.com/publichealthpolicy/fdageneral/120604
1 · Reply
LDstocks2023
LDstocks2023 Apr. 2 at 8:19 PM
$AQST thing fuckin sucks
0 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 6:50 PM
🐉 $AQST CALL — DragonAlgo® Signal Contract: AQST CALL Expiry: 2026-05-15 | Strike: $2.00 | Type: CALL Option Plan (premium): Entry: $2.12 Stop: $1.53 TP1: $2.76 TP2: $3.61 TP3: $5.10 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Golfnstock
Golfnstock Apr. 2 at 4:37 PM
$AQST so Eli Lilly’s weight lose drug was just approved and I had to chuckle at one of the comments listed “The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times. The agency said it reviewed the company's application in 50 days.” Let’s hope this bodes well for our resubmission
1 · Reply
BigGainTom
BigGainTom Apr. 2 at 3:25 PM
$AQST nice rally
1 · Reply
richb477
richb477 Apr. 2 at 3:42 AM
$AQST Needed in every licker room j
0 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 1:15 AM
🐉 $AQST CALL — DragonAlgo® Signal Contract: AQST CALL Expiry: 2026-05-15 | Strike: $2.00 | Type: CALL Option Plan (premium): Entry: $2.15 Stop: $1.55 TP1: $2.79 TP2: $3.65 TP3: $5.16 🔗 https://dragonalgo.com
0 · Reply
kibli
kibli Apr. 2 at 12:57 AM
$AQST Adults and families at risk for anaphylaxis prefer portable, easy-to-use epinephrine devices, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. https://www.healio.com/news/allergy-asthma/20260331/convenience-reliability-drive-epinephrine-preferences
0 · Reply
kibli
kibli Apr. 2 at 12:55 AM
$AQST Current law allows schools to use only auto-injectable epinephrine in emergencies. The proposed legislation would allow any Food and Drug Administration-approved epinephrine delivery system, including needle-free options. https://www.alreporter.com/2026/03/25/alabama-doctors-push-to-allow-needle-free-epinephrine-in-schools/
0 · Reply
LDstocks2023
LDstocks2023 Apr. 1 at 6:04 PM
$AQST doing what it does best!
0 · Reply
Stone52
Stone52 Apr. 1 at 5:23 PM
$AQST don’t miss out on the move!
0 · Reply
ae1213
ae1213 Apr. 1 at 5:11 PM
$AQST just stop posting your infantile drivel here and wait for the next spring time. Lets compare the notes then
2 · Reply
ae1213
ae1213 Apr. 1 at 5:04 PM
$AQST $SPRY you do realize that aqst has no chance to succeed, dont you? With their cash burn, tiny launch budget and approval (if any) in 12 months spry will leave no room for them and their gimmicky technology in the world wide market. Meanwhile spry will be sold within 12 months … can’t wait to see the acquisition price! Next 12 months will be continuous $AQST price decline to low 2s and some. Better sell here and buy $IOVA in 8 days below $2
4 · Reply
UnderLion16
UnderLion16 Apr. 1 at 3:58 PM
$AQST https://www.linkedin.com/posts/medicationsafetyweek-aqst-medicationsafety-share-7445123768026501121-kttB?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo
0 · Reply
TIG2
TIG2 Apr. 1 at 2:45 PM
$AQST Hay Mr. barber check (CYCN) one partner and their up 5+ bucks....Remember the partner Idea...
0 · Reply
UnderLion16
UnderLion16 Apr. 1 at 1:55 PM
0 · Reply
azv134
azv134 Apr. 1 at 1:39 PM
$AQST chart looks beautiful.. ready to take off!
3 · Reply
DragonAlgo
DragonAlgo Apr. 1 at 6:35 AM
🐉 $AQST CALL — DragonAlgo® Signal Contract: AQST CALL Expiry: 2026-04-17 | Strike: $6.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
kitty12345
kitty12345 Apr. 1 at 3:04 AM
$AQST Activity on the board has cooled off lately as most investors seem to be in a "wait-and-see" mode. Other stocks are offering more immediate catalysts compared to Aquestive’s approval timeline. However, since I expect the share price to steadily "inch" higher from here, I’m holding on tight to my shares.
1 · Reply